American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy¶
Hirsh, J., Fuster, V., Ansell, J., & Halperin, J. L. (2003). American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation, 107(12), 1692-1711.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Primes¶
- Selectivity Window
- In pharmacology, the therapeutic window is the dose range that discriminates efficacy from toxicity — below it no benefit, above it harm dominates, with warfarin the paradigm narrow case.
This sourceDefines warfarin's narrow therapeutic window via the INR target band (typically 2-3), with thrombosis below and hemorrhage above as the asymmetric edges.
Supported in partVerified against the work's full text
The guide shows warfarin safety and efficacy depend on holding INR in a therapeutic range, with events on both sides, but gives no general definition of a therapeutic window.
“The safety and effectiveness of warfarin therapy depends critically on maintaining the INR within the therapeutic range.”
- In pharmacology, the therapeutic window is the dose range that discriminates efficacy from toxicity — below it no benefit, above it harm dominates, with warfarin the paradigm narrow case.
Verification¶
Does it exist? Confirmed. This work's DOI resolves to a registered record, which fixes its identity. That is all it fixes.
Does it back the claim? Read against the text for 1 of 1 citation: 1 supported in part. Each verdict is shown under its citation below, with what in the work backs the sentence.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:0fcf47260579 · see in the full table